Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Lev Gertsik"'
Autor:
Daniel Umbricht, Markus Abt, Paul Tamburri, Christopher Chatham, Štefan Holiga, Michael J. Frank, Anne G.E. Collins, David P. Walling, Rick Mofsen, Daniel Gruener, Lev Gertsik, Jeff Sevigny, Sanjay Keswani, Juergen Dukart
Publikováno v:
Biological Psychiatry Global Open Science, Vol 1, Iss 1, Pp 70-77 (2021)
Background: Reduced activation of dopamine D1 receptor signaling may be implicated in reward functioning as a potential driver of negative symptoms in schizophrenia. Phosphodiesterase 10A (PDE10A), an enzyme that is highly expressed in the striatum,
Externí odkaz:
https://doaj.org/article/4e96e9575d7248e086f19bdc0d374f88
Autor:
Amit Desai, Gregory A. Light, Lev Gertsik, Tong Zhu, Paul Maruff, Tolga Uz, Lauren Benner, Ruishan Wu, Gerard J. Marek
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, vol 46, iss 6
ASP4345, a novel dopamine D1 receptor positive allosteric modulator, is being evaluated for the treatment of cognitive impairment associated with schizophrenia (CIAS). This phase 1 multiple ascending-dose study (NCT02720263) assessed the safety, tole
Autor:
Nicholas DeMartinis, Rene N. Lopez, David P. Walling, Adam Ogden, Christopher J. Schmidt, Eve H. Pickering, Lev Gertsik
Publikováno v:
Journal of Clinical Psychopharmacology. 39:318-328
Background Effective treatments for managing suboptimal clinical responses to current therapy for schizophrenia remain a critical unmet need. Phosphodiesterase 10A (PDE10A) inhibition represents a mechanistically novel approach to the treatment of sc
Autor:
Stefan Holiga, Daniel Umbricht, Rick Mofsen, Markus Abt, Michael J. Frank, Juergen Dukart, Sanjay Keswani, Lev Gertsik, Christopher H. Chatham, Daniel Gruener, Jeff Sevigny, Anne G.E. Collins, David P. Walling, Paul Tamburri
Publikováno v:
Biological psychiatry 1(1), 70-77 (2021). doi:10.1016/j.bpsgos.2021.03.001
Biological Psychiatry Global Open Science, Vol 1, Iss 1, Pp 70-77 (2021)
Biological Psychiatry Global Open Science, Vol 1, Iss 1, Pp 70-77 (2021)
Background Reduced activation of dopamine D1 receptor signaling may be implicated in reward functioning as a potential driver of negative symptoms in schizophrenia. Phosphodiesterase 10A (PDE10A), an enzyme that is highly expressed in the striatum, m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::055794a1effef60fcc6fd99358a3cd1d
https://hdl.handle.net/2128/28586
https://hdl.handle.net/2128/28586
Autor:
Molly Sherman, Lev Gertsik, Lovingly Park, Svetlana Semenova, Zyanya Mendoza, Claudia Aguilar, Stanford Jhee, Lydia Morris
Publikováno v:
Alzheimer's & Dementia. 16
Publikováno v:
Clinical Pharmacokinetics
Background Cognitive impairment is a core feature of schizophrenia. While first- and second-generation antipsychotic drugs treat psychotic exacerbations, no treatment is approved for the cognitive dysfunction. We have identified ASP4345, a positive a
Autor:
Paul Goldsmith, Maggie McCue, Jinhui Xie, Stefan Roepcke, Thomas A. Macek, Lev Gertsik, Max Tsai, John Affinito
Publikováno v:
Drugs in R&D
Background Phosphodiesterase 10A (PDE10A) is selectively expressed in medium spiny neurons of the striatum. TAK-063 is a selective inhibitor of PDE10A in clinical development for the treatment of schizophrenia. Objectives Safety, tolerability, and ph
Autor:
D. Gullaba, Svetlana Semenova, Zyanya Mendoza, Lovingly Park, Sophie Lee, C. Kouhanim, C. Aguilar, K. Patrick, Lev Gertsik, Stanford Jhee
Publikováno v:
The journal of prevention of Alzheimer's disease. 6(2)
Background: The recruitment challenges for MCI and AD subjects into clinical trials are well known, and this is particularly true for early phase studies. Currently, only 10-20% of all patients who are referred for research from the community are tri
Autor:
Annette Stevenson, Mary Corcoran, Bryan Dirks, Patrick Martin, David P. Walling, Aparna Raychaudhuri, Lev Gertsik, James Ermer
Publikováno v:
Journal of Clinical Psychopharmacology. 34:682-689
To assess the safety and pharmacokinetics of lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, this double-blind study enrolled adults with clinically stable schizophrenia who were adherent (≥12 weeks) to antipsychotic pharmacotherapy. Th
Publikováno v:
British Journal of Clinical Pharmacology. 77:965-974
Aims ABT-288 is a potent and selective H3 receptor antagonist with procognitive effects in several preclinical models. In previous studies, 3 mg once daily was the maximal tolerated dose in healthy volunteers. This study characterized the safety, tol